Lansforsakringar Fondforvaltning AB publ bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 27,152 shares of the company's stock, valued at approximately $11,226,000.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. PKO Investment Management Joint Stock Co bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $1,158,000. Centaurus Financial Inc. lifted its holdings in shares of IDEXX Laboratories by 23.3% in the fourth quarter. Centaurus Financial Inc. now owns 280 shares of the company's stock valued at $116,000 after purchasing an additional 53 shares in the last quarter. Dogwood Wealth Management LLC lifted its holdings in shares of IDEXX Laboratories by 16.9% in the fourth quarter. Dogwood Wealth Management LLC now owns 1,490 shares of the company's stock valued at $616,000 after purchasing an additional 215 shares in the last quarter. Menard Financial Group LLC bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $45,000. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of IDEXX Laboratories in the fourth quarter valued at about $38,818,000. 87.84% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of brokerages have recently commented on IDXX. Stifel Nicolaus boosted their price target on IDEXX Laboratories from $460.00 to $510.00 and gave the company a "hold" rating in a report on Monday, May 19th. Bank of America upped their target price on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a report on Tuesday, February 4th. Barclays upped their target price on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a report on Tuesday, February 4th. Morgan Stanley upped their target price on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a report on Monday, May 5th. Finally, Wall Street Zen lowered IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday. Four investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $536.00.
Check Out Our Latest Report on IDXX
Insider Buying and Selling
In related news, Director M Anne Szostak sold 1,260 shares of the stock in a transaction that occurred on Wednesday, May 21st. The stock was sold at an average price of $512.34, for a total transaction of $645,548.40. Following the sale, the director now owns 1,801 shares of the company's stock, valued at $922,724.34. This represents a 41.16% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. 0.98% of the stock is currently owned by company insiders.
IDEXX Laboratories Stock Performance
Shares of IDEXX Laboratories stock traded down $3.03 on Friday, hitting $512.52. The stock had a trading volume of 1,221,827 shares, compared to its average volume of 652,599. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $530.60. The business's 50 day moving average is $449.80 and its two-hundred day moving average is $437.32. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a market cap of $41.22 billion, a price-to-earnings ratio of 48.03, a price-to-earnings-growth ratio of 3.41 and a beta of 1.52.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to the consensus estimate of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The firm's quarterly revenue was up 3.6% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.71 earnings per share. Analysts forecast that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
See Also
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
